The Effect of Prucalopride on Small Bowel Transit Time in Hospitalized Patients Undergoing Capsule Endoscopy

Table 1

Baseline characteristics of study population, the prucalopride versus the control group.

Patient characteristic	Prucalopride	Control	value
Age mean, year (SD)	64.4 (13.9)	65.2 (16.4)	0.85
Male	20 (68.9%)	15 (60%)	0.49
Indication			1
Overt OGIB	26 (89.6%)	23 (92%)
Occult OGIB	1 (3.4%)	1 (4%)
Abnormal radiology	2 (6.8%)	1 (4%)
Medical comorbidities
Cardiac disease	11 (37.9%)	12 (48%)	0.52
Congestive heart failure	5 (17.2%)	7 (28%)	0.37
Valvular heart disease	8 (27.5%)	5 (20%)	0.46
Cerebrovascular disease	3 (10.3%)	5 (20%)	0.45
Chronic kidney disease	4 (13.7%)	1 (4%)	0.35
Chronic lung disease	2 (6.8%)	2 (8%)	1
Liver cirrhosis	3 (10.3%)	0 (0%)	0.23
Diabetes	8 (27.5%)	7 (28%)	0.97
Antiplatelets (ASA and/or plavix)	11 (37.9%)	7 (28%)	0.44
NSAIDS	2 (6.8%)	2 (8%)	1
Anticoagulants	6 (20.6%)	5 (20%)	0.95
Narcotics	3 (10.3%)	1 (4%)	0.61

SD, standard deviation; OGIB, obscure gastrointestinal bleeding; NSAIDS, nonsteroidal anti-inflammatory drugs.